Why the study?
Does cisplatin-based chemotherapy increase the risk of arterial thromboembolic events in patients with solid tumors compared to non-cisplatin-based chemotherapy?
Does cisplatin-based chemotherapy increase the risk of arterial thromboembolic events in patients with solid tumors compared to non-cisplatin-based chemotherapy?
This meta-analysis found no statistically significant increase in the risk of arterial thromboembolic events associated with cisplatin-based chemotherapy in patients with solid tumors.
No takes yet. Share an insight, caveat, or question.
No increased arterial thromboembolic risk with cisplatin; challenges prior safety concerns while leaving open modest effects in select populations.
Proverbs‐Singh et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: